Lucy Donaldson - Nottingham BRC

Lucy Donaldson is a neurophysiologist with expertise in neuronal function in acute and chronic pain, particularly in arthritis but also other painful conditions.

Lucy studied for her undergraduate (Dentistry BDS, Neuroscience BSc (Hons)) and postgraduate (PhD, Pharmacology) degrees at the University of Edinburgh. From there she moved to a post-doctoral position at the University of California, working on several projects including tachykinin receptor expression and function, neuronal cation-chloride co-transporters and protein kinases . In 1996 she was appointed to a Lectureship at the University of Leicester, where she worked on neuronal prostaglandins in collaboration with Blair Grubb. In 1999 she moved to the Dept of Physiology, University of Bristol, where she has worked on multiple projects ncluding TRP channel, cyclooxygenase and galanin contributions to primary afferent nociceptor function (MRC, Arthritis Research UK funded), neuronal mechanisms in arthritic symmetry (Wellcome Trust funded), descending prostanergic facilitatory control systems (BBSRC, MRC funded, with Prof Bridget Lumb), mTOR peripheral translation mechanisms (MRC funded, with Profs Lumb and Hunt), and vascular endothelial growth factors in neuroprotection and pain (funded by Diabetes UK and Arthritis Research UK). During this time she also developed a research program in human taste perception in health and disease, with particular focus on taste and depression/anxiety, in collaboration with Jan Melichar. In September 2013, Lucy moved to Life Sciences at the University of Nottingham, where she is now Professor of Sensory Physiology. The main focus of her current work is still in pain, looking at novel analgesic mechanisms for neuropathic and arthritic pain, particularly focussing on alternative RNA splicng.

She is a co-founder of a University of Nottingham spin-out company Exonate Ltd, a biopharmaceutical company focussed on the discovery and development of small molecule drugs that modulate alternative mRNA splicing to address diseases of high unmet medical need.

For further details: Lucy Donaldson